We propose a class of Bayesian cure rate models by incorporating a baseline density function as well as multiplicative and additive covariate structures. Our model naturally accommodates zero and non-zero cure rates, which provides an objective way to examine the existence of a survival fraction in the failure time data. An inherent parameter constraint needs to be incorporated into the model formulation due to the additive covariates. Within the Bayesian paradigm, we take a Markov gamma process prior to model the baseline hazard rate, and mixture prior distributions for the parameters in the additive component of the model. We implement a Markov chain Monte Carlo computational scheme to sample from the full conditional distributions of the posterior. We conduct simulation studies to assess the estimation and inference properties of the proposed model, and illustrate it with data from a bone marrow transplant study.
INTRODUCTION
In many clinical trials, particularly in oncology research, a certain percentage of patients may be cured and thus become risk-free of a specific event of interest or disease relapse [36] . On the other hand, a study may involve a proportion of subjects who are insusceptible to the event of interest, while the rest are susceptible. In either case, the risk set at a given time point during the follow-up needs to exclude those cured or insusceptible subjects [19] . Many interesting examples of such data are from bone marrow transplant (BMT) research. BMT is a procedure to replace bone marrow that has been destroyed by treatment with high doses of anticancer drugs or radiation. Transplantation can be classified into three types: autologous (the patient's own marrow saved before treatment), allogeneic (marrow donated by someone else), or syngeneic (marrow donated by an identical twin). During the transplant, a common complication, known as the graftversus-host disease (GVHD), is a reaction of donated stem cells against patients' tissue. In general, patients are less * Corresponding author.
likely to develop GVHD if the stem cells of the donor and patient are closely matched. After treatment, patients receive the harvested stem cells, which travel to the bone marrow and begin to produce new blood cells. To minimize potential side effects, doctors most often use transplanted stem cells that match the patient's own stem cells as closely as possible. The matching is usually based on the proteins on the surface of the cells, namely the human leukocyte-associated antigens (HLA). Szydlo et al. [38] studied leukemia patients with BMT from HLA-identical siblings, HLA-matched and mismatched unrelated donors. The primary end point was the time to cancer relapse or death while in remission. Although death would eventually occur if the follow-up is long enough, the definition for cure depends on the study duration and the nature of the disease. In fact, due to the GVHD, most of the BMT studies share the common feature: the GVHD typically causes the occurrence of death quickly as shown by the estimated Kaplan-Meier survival curves for the three donor groups in Figure 1 . Patients may be considered "cured" if they could survive the risk of the GVHD after the transplant. After approximately five years follow-up, we observe a stable plateau for each arm, which indicates a possible cure fraction in this patient population.
Most of the survival models in the literature are based on a fundamental assumption that all the "alive" subjects are at risk, under which a cure fraction is typically not allowed. However, cure rate models are explicitly constructed to incorporate a survival fraction. In particular, for subject i with covariate vector Z i , let S pop (t|Z i ) denote an improper population survival function, i.e., lim t→∞ S pop (t|Z i ) > 0. Let S(t) denote a proper survival function corresponding to those uncured or susceptible subjects, i.e., lim t→∞ S(t) = 0. By mixing a certain fraction 1 − θ(Z i ) of the population as being cured and the rest θ(Z i ) not cured, Berkson and Gage [3] proposed the two-component mixture cure rate model,
The covariates Z i characterize the long-term survival effects, which can be linked via θ(·) in a logistic form, θ(Z i ) = exp(β Z i )/{1 + exp(β Z i )}. Extensive research has been carried out with the mixture cure rate model [18, 25, 31, 33, 37, 2] . Although the mixture cure rate model is quite intuitive, it lacks the proportional hazards structure [11] and other desirable properties as noted in Chapter 5 of [19] . In an alternative formulation, the cure rate model proposed by Yakovlev et al. [41] maintains the multiplicative structure of the proportional hazards model [39, 6, 20] . The population survival function is given by
where F (t) is a proper cumulative distribution function (c.d.f.), and the covariate structure takes the form of θ(Z i ) = exp(β Z i ). Ignoring the impropriety of S pop (t|Z i ) in (1.2), we can compute the population hazard function as
where f (t) is the density function corresponding to F (t). Chen et al. [6] showed that under certain mild conditions, a uniform improper prior distribution for the regression parameters in (1.2) still leads to a proper posterior distribution, while an improper prior typically yields an improper posterior under model (1.1). Tsodikov et al. [40] provided a comprehensive review of the recent developments of model (1.2). More recently, cure rate models have been studied in a variety of contexts, such as the interval censored data [26] , jointly modeling longitudinal and cure survival data [5] and cure rate modeling through latent activation schemes [9] . In this article, we consider an encompassing model
in which either β or γ contains an intercept, but not both, for identifiability. As the hazard function must be nonnegative for all t, and f (t) ≥ 0, the parameter constraint, γ X i ≥ 0, needs to be satisfied throughout. This constraint is in accordance with other additive hazards models [27] .
Model (1.3) has a non-zero cure rate only when γ = 0, and all the other values of γ correspond to a proper survival function, because
It is critical to assess whether there exists a survival fraction in the data, since it is a fundamental assumption for the application of cure rate models [29, 30, 34, 22] . In practice, the validity of cure rate modeling is often examined empirically by the Kaplan-Meier survival curve. The ability to accommodate both cure and non-cure formulations in model (1.3) is particularly interesting, which offers an objective way to distinguish the model fitting between cure and noncure models. Many flexible hazard-based regression models have been studied by incorporating multiplicative and additive covariate structures [4, 27, 28, 35] . However, in the context of cure rate models, very limited research has been conducted along this direction.
The rest of this article is organized as follows. In Section 2, we introduce notation and derive the likelihood function. Moreover, we specify mixture prior distributions for the parameters in the additive component of the model, and a Markov gamma process to model the baseline hazard rate. In Section 3, we obtain the full conditional distributions of the posterior to implement the Gibbs sampling. In Section 4, we conduct simulation studies and present a full Bayesian analysis of the BMT data. Finally, we give a brief discussion in Section 5.
LIKELIHOOD AND PRIOR
For i = 1, . . . , n, let T i be the failure time, C i be the censoring time, and ν i = I(T i ≤ C i ) be the censoring indicator for the ith subject. The covariates are denoted by Z i and X i , which may share common components. The observed data D = {Y i = min(T i , C i ), ν i , Z i , X i } are independent and identically distributed for i = 1, . . . , n. We assume that T i is conditionally independent of C i given covariates Z i and X i . For notational brevity, let Ga(α, ξ) denote a gamma distribution with mean α/ξ, Poi(c) a Poisson distribution with mean c and Ber(a) a Bernoulli probability function of taking a value of 1 with probability a.
Under model (1.3), the likelihood function is given by
where f (t) and F (t) are the baseline density and distribution functions, respectively. More explicitly,
λ(s)ds}, and λ(t) is the corresponding baseline hazard function. We discretize the time axis into J nonoverlapping intervals such that 0 = s 0 < s 1 < · · · < s J , and s J > y i for all i = 1, . . . , n, we then define the baseline hazard rate
We define the partition in such a way that the number of failures in each interval is balanced.
To define the prior on λ(t), we introduce latent Poisson variables {u j } to generate a Poisson-gamma alternating process to model f (t) and F (t). Let λ and u denote the vectors of λ j and u j , and λ (−j) and u (−j) denote the rest of the vectors after deleting the jth component, respectively. We define δ ij = 1 if subject i fails or is censored in interval j, and 0 otherwise. The likelihood function based on the Markov gamma process is given by
Instead of assigning independent gamma prior distributions to the λ j 's, we employ a correlated Markov gamma process to model λ(t):
where the c j 's are the smoothing parameters to induce correlations between the λ j 's [32] . In the special case when all the c j 's are zero, u j = 0 with probability one, and the λ j 's become independent. By introducing the latent Poisson process {u j }, the components of {λ j } are naturally correlated a priori, and each λ j has a gamma prior distribution given u j−1 . The advantages of introducing a latent Poisson process are that it formulates dependence between the λ j 's, which is more realistic in practice and facilitates modeling the trend of the hazard; the Poisson latent variables simplify posterior simulations due to conjugacy; and when the α j 's and ξ j 's are all equal, the prior process is stationary. Other prior specifications on {λ j } can impose correlations as well, such as using a first-order autoregressive structure or a Markovian relation [12, 1, 21] .
Although not required for the development, we take β, γ and (λ, u) to be independent a priori, i.e., π(β, γ, λ, u) = π(β)π(γ)π(λ, u). The joint prior distribution of (λ, u) can be written as
Without loss of generality, we assume that all the covariates are positive, which can be easily shifted and rescaled if this is not the case in practice. The prior distribution for each component of β can simply be a zero-mean normal distribution with a large variance. However, we need to be more cautious with the prior specification on γ due to the constraint γ X i ≥ 0 (i = 1, . . . , n). Parameter constraints often make Bayesian computation more complicated [14, 15, 8] . In order to calibrate the posterior probability of γ = 0, we consider a mixture of two zero-mean normal distributions (one with a small variance and the other with a large variance) for each component of γ, as in the stochastic search variable selection (SSVS) developed by George and McCulloch [16] .
More specifically, we take that
where q is the length of vector γ, 0 < a 0 < 1, h > 1, and σ is relatively small. This implies that if γ k takes a sample from the posterior distribution corresponding to N (γ k |0, σ 2 ) in the mixture, we can "safely" set γ k = 0.
This construction implies that, a priori, γ k |γ (−k) has a mixture of two truncated normal densities with a small vari-ance of σ 2 and a large variance of
The two truncated normal distributions, one with a small variance (h = 1) and the other with a large variance (h > 1), can be written as
where
and the normalizing constant
To facilitate the implementation of the Markov chain Monte Carlo (MCMC) method, we introduce a latent Bernoulli random variable w k . We rewrite the conditional prior of γ k given w k and γ (−k) as
with w k ∼ Ber(a 0 ) for k = 1, . . . , q. By mixing the two truncated normal densities, we are able to assess the existence of a cure through the posterior samples of w = (w 1 , . . . , w q ) . If the proportion of w = 0 is high in the posterior samples, it tends to support the fit of a cure rate model.
POSTERIOR COMPUTATION
We derive the full conditional distributions for the parameters (β, γ, λ, u, w) to implement the Gibbs sampling. The full conditional distribution of β does not depend on the latent Poisson or Bernoulli variable, thus,
where π(β) is a normal prior distribution. The full conditional distribution for λ simplifies to the following expression,
for j = 1, . . . , J, and c 0 = c J = 0 and u 0 = u J = 0 with probability one. Since u does not depend on the observed data,
, where
.
Even though the mixture prior has a similar flavor as that in the SSVS [16] , our focus is quite different. In fact, the fundamental model structure in our case changes during the Gibbs iterations. The Markov chain alternately visits between a non-cure model with a proper survival function (when γ = 0) and a cure model with an improper survival function (when γ = 0). The posterior probability of supporting a cure rate model can be estimated by averaging the indicator variables w k across all the MCMC iterations, i.e., to obtain the proportion of γ k = 0. Due to the non-logconcavity of the full conditional distributions, a Metropolis step is required within the Gibbs sampler [17] .
NUMERICAL STUDIES

Simulation
We carried out two simulation studies to examine the performance of the proposed method. We generated the failure times from the multiplicative-additive cure model (1.3). In particular we considered,
The baseline density function was chosen as an exponential distribution with mean one, i.e., the baseline hazard function is one. Both covariates Z and X were simulated from a Bernoulli random variable, taking a value of 0 or 1 with probability 0.5. The censoring times were independently generated from a uniform distribution. The true parameter values were β 0 = −0.2 and β 1 = 1. For the first simulation study, we took γ = 0, i.e., the underlying true model did not have an additive covariate component, which led to a cure rate model. On the other hand, for the second simulation study, we took γ = 1, which led to a cure rate model when X = 0 and to a non-cured model when X = 1. Such a covariate-dependent cure rate model structure typically cannot be accommodated by the available methods in the literature. We took the sample size n = 300 and replicated 500 simulations. For the model with γ = 0, the cure rate is given by exp{− exp(β 0 +β 1 Z)}. The true cure rate for the group with Z = 0 is 44% and that for Z = 1 is 11%. In Figure 2 , we show the estimated Kaplan-Meier survival curves of each arm for the first 50 simulated data sets. We observe a common pattern with sharp drops at the beginning of the follow-up, and stable plateaus at the tails of the curves, which resembles the survival curves of the BMT data in Figure 1 . For the model with γ = 1, our model specifies four groups by the combination of the two values of covariates Z and X. The Kaplan-Meier survival curves for these four groups of the first 50 simulated data sets are shown in Figure 3 , from which we clearly see cure rate patterns (the first column) as well as non-cure ones (the second column) arising from the same model. For each data realization, we fit the proposed model with different values of (σ, h) to examine the percentage of the posterior samples of γ being zero. We took vague prior distributions for all of the model parameters so that the likelihood would dominate the posterior estimation. Under each configuration, we recorded 5,000 MCMC iterations after the first 100 burn-in samples in the Gibbs sampling. The posterior means and standard deviations of the parameters were computed based on the 5,000 posterior samples.
In Table 1 , we report the posterior mean and standard deviation averaged over 500 simulations for each regression parameter. We can see that the posterior means of the parameters are quite close to the true values, indicating that the MCMC chains converged properly. In simulation 1 with the true γ = 0, even under the misspecified model, the posterior estimates for β 0 and β 1 were close to the true values. Across different pairs of (σ, h), there were high posterior probabilities that the additive part of model (4.1) did not exist, because a high percentage of the posterior samples of γ were zero. In simulation 2 with the true γ = 1, the percentage of the posterior samples of γ being zero was very low. In addition, when the variance of the sharp normal distribution was very small and that of the flat normal distribution was very large, Pr(γ = 0|D) was very close to zero. This demonstrates the usefulness of the proposed model for detecting the survival fraction in the data, which provides an 
BMT example
As an illustration, we applied the proposed method to analyze the BMT data. Transplants were performed between 1985 and 1991, and reported to the International Bone Marrow Transplant Registry [23] . In this analysis, we had 1,715 patients with acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). The time to cancer relapse or cancer death while in remission was the primary end point, and was recorded in months. The covariates of interest included three donor types: HLA-identical sibling, HLA-matched unrelated and mismatched unrelated; three disease types: ALL, AML and CML; three stages of disease: early, intermediate and advanced; and Karnofsky score (taking a value of 1 if the Karnofsky score ≥ 90, 0 otherwise). We created two indicator variables for each of the three categorical variables by taking the HLA-identical sibling, ALL, and early stage of disease as the baseline, respectively. In our analysis, we were particularly interested in whether a cure rate model was appropriate for the BMT data, for which we studied the model
where (Z 1 , . . . , Z 7 ) corresponded to the covariates in Table 2. We partitioned the time axis from zero up to 94 months into a total of J time intervals, and we took J = 5, 10 and 20, for comparison. We balanced the number of failures in each interval. Therefore, the intervals are shorter during the earlier follow-up and longer at the later times, since events occurred more frequently in the first 30 months. To determine the best fitting model with different J values, we computed the log-pseudo marginal likelihood (LPML) as the model selection criterion to choose the best J. In particular, the LPML is related to the conditional predictive ordinate (CPO) statistic [13, 14] . CPO is a Bayesian cross-validation statistic by computing the conditional predictive distribution after deleting a single observation, which measures the adequacy of a model.
Let D (−i) denote the data with the ith observation deleted. We denote the density function of y i by f (y i |Z i , X i , β, γ, λ) , and the posterior density of (β, γ, λ)
The CPO i is the marginal posterior predictive density of y i given D (−i) , which can be written as
A Monte Carlo approximation of CPO i [8] is given by
where M is the number of Gibbs samples after burn-in, and β [m] , γ [m] and λ [m] are the samples of the mth Gibbs iteration. Note that In the Bayesian analysis, we took vague priors for all the model parameters so that the likelihood dominated the posterior inference. In particular, we took α j = ξ j = 0.01 for j = 1, . . . , J. We specified a normal prior with mean zero and variance 100 for each component of β. As to the prior distribution of γ, we took a mixture of two truncated normal densities with the corresponding variances σ 2 and h 2 σ 2 . We took a 0 = 0.5 so that the prior probability of γ from each normal distribution in the mixture was the same. We monitored the MCMC convergence using the methods recommended by Cowles and Carlin [10] , and observed that the chain converged fast and mixed well. We recorded one posterior sample every five iterations to reduce the autocorrelation from 20,000 Gibbs samples after 2,000 burn-ins.
We first fixed c j = 100 and (σ = 0.1, h = 100), but varied J = 5, 10 and 20. We obtained the corresponding LPML statistics of −3416.2, −3411.5 and −3405.6, and thus the model with J = 20 was deemed as the best fit. Table 2 summarizes the posterior mean, standard deviation and 95% highest posterior density (HPD) interval for each model parameter. Moreover, we carried out a sensitivity analysis by choosing different values of (σ, h) in the mixture prior of two normal densities, see Table 3 . We can see that the posterior estimates are quite similar for different paired values of (σ, h). Patients treated with the BMT from HLA-matched unrelated donors or mis-matched unrelated donors had significantly worse survival than those with HLA-identical sibling donors. The stage of disease significantly affected survival: more advanced disease stages clearly led to shorter survival. There was not much difference between survival across the three disease types. For a wide range of paired values of (σ, h) = (.33, 10), (.01, 100), and (.001, 100), the posterior probabilities of γ = 0: Pr(γ = 0|D) = .910, .990 and .966, respectively. Therefore, there are consistently high posterior probabilities, above 90%, indicating that γ = 0. Our model strongly supports a cure rate model structure by eliminating the additive component from model (4.2). Moreover, we fixed J = 20, and took c j = 0, 10, 50 and 100 to smooth and correlate the baseline hazard rates, respectively. Figure 4 presents the posterior means of the baseline hazard rate λ(t) for c j = 0, 10, 50 and 100, respectively. The hazard estimate with c j = 0 imposes an independent gamma process prior, and a larger value of c j induces a higher correlation in the gamma process. These four plots exhibit a very similar pattern. During the early follow-up, the baseline hazard appeared to be much higher, which resulted in more occurrences of events, that would correspond to the sharp drops of the survival curves in Figure 1 . In the later follow-up period, the hazard decayed to a lower level and became more stable, matching with the plateaus at the tails of the Kaplan-Meier survival curves.
DISCUSSION
We have proposed a class of flexible Bayesian hazard regression models by incorporating the multiplicative and additive covariate structures. It naturally provides an objective assessment of the existence of a survival fraction in the data. Due to the nonnegativity of a hazard function, we impose a parameter constraint on the additive component of our model, that is, γ X i ≥ 0. As pointed out by a referee, to avoid the constraint we could define the additive part to be of the form |γ X i |. However, we need to be cautious with the interpretation of the parameter γ because a positive or negative change in the covariate X i would imply the same change in the hazard. Furthermore, we use a mixture prior distribution for the parameters associated with the additive component in the model. An alternative mixture prior involving a point mass at zero instead of a sharp density can also be considered. In our numerical experience, posterior inference is more stable with the mixture of two normal distributions.
A Markov gamma process prior is specified for the baseline hazard to facilitate the full Bayesian semiparametric estimation. Gibbs sampling can be easily implemented for the resulting model, from which it is straightforward to compute the posterior probability of a cure rate model. The proposed method links the proper and improper population survival functions through the multiplicative and additive components of the covariate structure. This family of cure rate models is widely applicable due to its flexibility, particularly for modeling two treatment groups where a cure fraction is only present in one group but not in the other. Such a situation has been illustrated in the simulation study.
